FRNM news sentiment

Freenome (FRNM) 10K Form and Latest SEC Filings 2026

This article provides an overview of Freenome's (FRNM) SEC filings, highlighting that the company has submitted over 82 documents since 2024. It details various filing types like 10-K, 10-Q, 8-K, and Form 4, explaining their significance for investors. The most recent filing mentioned is a Form SCHEDULE 13G/A submitted on August 14, 2026.

Freenome (FRNM) posts $132.6M loss but raises $295.5M via SPAC and PIPE

Freenome Inc. reported a net loss of $132.6 million for the first half of 2026, widening from the previous year, and used $97.1 million in operating cash. Despite these losses and an accumulated deficit of $1.5 billion, the company secured $295.5 million in net proceeds from a SPAC business combination and PIPE financing. This capital, along with existing liquidity, is expected to fund operations for at least 12 months, supporting ongoing R&D and commercialization efforts, especially after the recent FDA approval of its SimpleScreen™ CRC test.

Form 8K Freenome Inc For: 13 August By Investing.com

This article from Investing.com announces that Freenome Inc. filed a Form 8K for August 13. The content of the filing itself is not detailed, as the article primarily serves as a notification of the filing. It mentions the stock symbol FRNM and provides general market data and other news.

Freenome targets lung screening gap; only about 18% of U.S. adults recommended get screened

Freenome has received FDA Breakthrough Device Designation for its investigational SimpleScreen™ Lung test, a blood-based screening tool for lung cancer. The test is designed for high-risk adults aged 50-80 with a significant smoking history who are not currently undergoing recommended screening, aiming to address the substantial screening gap where only about 18% of eligible U.S. adults get screened. While the designation accelerates the review process and is a positive step, the market reacted with a slight decline in FRNM stock, as the test remains investigational and not yet FDA approved for routine use.

Freenome, Inc. (FRNM) stock price, news, quote and history

This article provides an overview of Freenome, Inc. (FRNM) stock performance, including its current price, news, and historical data. It details the company's stock price movement, key financial metrics like trailing total returns against the S&P 500, and lists relevant market data. The content also includes a snapshot of market activity for various indices and commodities.

Freenome Holdings Number of Employees 2026 | Employee Count & Headcount Data

Freenome Holdings, a Biotech and Healthcare Services company founded in 2014 and headquartered in Brisbane, California, had approximately 527 employees worldwide as of March 2026. This represents a 26.8% decline from 719 employees in 2023, though the company saw a slight increase from a low of 519 in Q4 2025. The workforce is concentrated in the United States (74.8%), with an average salary of $149,649, and the company is actively hiring with 42 job postings in 2026.

FRNM | Freenome, Inc. Common stock Stock Data, Price & News

Freenome, Inc. (FRNM) Company Information

This article provides company information for Freenome, Inc. (FRNM), including its key details like ticker, exchange, founding year, industry, and market capitalization. It also outlines the data sources used for the company analysis, such as financial statements, analyst estimates, and market prices, and mentions that Freenome, Inc. is not covered by any analysts for revenue or earnings estimates.

Freenome, Inc. (PCSC) CPO details common stock and multiple option grants

Freenome, Inc. (PCSC) director reports common stock and option stakes

Freenome, Inc. (FRNM) CFO discloses initial share and stock option positions

Operating cash flow per share of Freenome, Inc. – NASDAQ:FRNM

This article focuses on the operating cash flow per share of Freenome, Inc. (NASDAQ: FRNM). It appears to be a financial data page from TradingView, providing financial metrics for the biotechnology company. The page indicates market status and provides navigation to other financial details.

Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection

Freenome, an early cancer detection company, has become publicly traded on the Nasdaq Capital Market under the ticker "FRNM" after completing its business combination with Perceptive Capital Solutions Corp. The company raised over $300 million in gross proceeds, which will fund the expansion of its cancer screening portfolio, AI/ML-enabled multiomics platform, and commercial infrastructure. Freenome aims to make early cancer detection simple, accessible, and personalized, focusing on blood-based tests for various cancer types, starting with colorectal cancer.